The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- Medicare Denied the Only Drug That Worked for My Rare Disease. A Canadian Pharmacy Made It Affordable.
- FSR Welcomes Nine New Members to the FSR Global Sarcoidosis Clinic Alliance
- National Lung Transplant Awareness Day
- Celebrating Over a Year of the New FSR Patient Registry Platform
- In Memory of Brenda Harris